劳拉西泮在儿童癫痫持续状态中的群体药代动力学与探索性药效学
该研究合并两项儿童临床试验数据,建立静脉劳拉西泮在3月龄至17岁癫痫持续状态患儿中的群体药代动力学模型,共145例患者提供439个样本。采用二室模型加异速增长可较好描述数据,年轻年龄与略高的体重归一化清除率相关,模拟支持统一按0.1 mg/kg(最大4 mg)给药可达50-100 ng/mL目标浓度。
要点
- 儿童癫痫持续状态静脉劳拉西泮可用二室模型加异速增长描述。
- 除体重外,较年轻年龄与略高的体重归一化清除率相关。
- 模拟提示0.1 mg/kg(最大4 mg)可达50-100 ng/mL目标浓度。
核心结论
- 采用稀疏采样和二室模型成功描述了儿童癫痫持续状态患者静脉劳拉西泮的群体药代动力学。
研究设计与样本
- 合并两项儿童临床试验数据,采用NONMEM软件建立群体药代动力学模型并评估暴露-反应关系及进行给药模拟。
- 共145例3月龄至17岁癫痫持续状态患儿,贡献439个药代动力学样本。
主要发现
- 中位年龄5.4岁(范围0.3-17.8),中位剂量0.10 mg/kg(范围0.02-0.18)。
- 二室模型加异速增长可较好描述数据,除总体重外较年轻年龄与略高的体重归一化清除率相关。
- 未发现药代动力学参数与临床结局相关。
关键数值与推荐
- 典型值关系:V1(L)=0.879*WT;CL(L/h)=0.115*(Age/4.7)^0.133*WT^0.75;V2(L)=0.542*V1;Q(L/h)=1.45*WT^0.75。
- 模拟提示统一儿童剂量0.1 mg/kg(最大4 mg)可在癫痫持续状态患儿中达到50-100 ng/mL浓度。
临床怎么用
- 儿童癫痫持续状态静脉劳拉西泮可按0.1 mg/kg(最大4 mg)给药,以期达到既往与有效惊厥控制相关的50-100 ng/mL浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lorazepam is one of the preferred agents used for intravenous treatment of status epilepticus (SE). We combined data from two pediatric clinical trials to characterize the population pharmacokinetics of intravenous lorazepam in infants and children aged 3 months to 17 years with active SE or a history of SE. METHODS: We developed a population pharmacokinetic model for lorazepam using the NONMEM software. We then assessed exploratory exposure-response relationships using the overall efficacy and safety study endpoints, and performed dosing simulations. RESULTS: A total of 145 patients contributed 439 pharmacokinetic samples. The median (range) age and dose were 5.4 years (0.3-17.8) and 0.10 mg/kg (0.02-0.18), respectively. A two-compartment pharmacokinetic model with allometric scaling described the data well. In addition to total body weight (WT), younger age was associated with slightly higher weight-normalized clearance (CL). The following relationships characterized the typical values for the central compartment volume (V1), CL, peripheral compartment volume (V2), and intercompartmental CL (Q), using individual subject WT (kg) and age (years): V1 (L) = 0.879*WT; CL (L/h) = 0.115*(Age/4.7)0.133*WT0.75; V2 (L) = 0.542*V1; Q (L/h) = 1.45*WT0.75. No pharmacokinetic parameters were associated with clinical outcomes. Simulations suggest uniform pediatric dosing (0.1 mg/kg, to a maximum of 4 mg) can be used to achieve concentrations of 50-100 ng/mL in children with SE, which have been previously associated with effective seizure control. CONCLUSIONS: The population pharmacokinetics of lorazepam were successfully described using a sparse sampling approach and a two-compartment model in pediatric patients with active SE.
引用
- Gonzalez D, Chamberlain JM, Guptill JT, et al. Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus. Clin Pharmacokinet. 2017. PMID: 27943220. doi:10.1007/s40262-016-0486-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。